跳到正文
原文
MedPage Today·· 9 天前AI 评分50

RA患者在更年期经历更严重的症状

Rheumatoid Arthritis Does Not Improve the Menopause Experience

AI 导读

一项研究发现,RA患者在更年期的症状比非RA患者更严重,特别是睡眠障碍和关节疼痛。研究者建议风湿科医生在治疗RA时考虑患者的更年期状况。

正文

— Quite the opposite, study indicates

by John Gever, Contributing Writer, MedPage Today

November 11, 2026 • 3 min read

ORLANDO -- Women with rheumatoid arthritis (RA) had a worse menopause experience compared with the non-RA individuals going through the transition, a researcher reported here.

Symptom severity, as evaluated with the Menopause Rating Scale (MRS), was significantly greater among menopausal RA patients versus other participants in two registries maintained by the Mayo Clinic, with mean scores of 15 as compared with 13 across both cohorts (P<0.001), according to Kristen J. Young, DO, of the Mayo's location in Phoenix.

Moreover, 72% of the RA patients reported a "clinically significant symptom burden," versus 57% in the entire sample (P<0.001), she told attendees at the American College of Rheumatology's annual meeting.

Individual menopausal symptoms including fatigue, sleep disturbance, joint pain, and mood changes appeared worse with RA. Because these are also symptoms of RA, one could also look at these data and conclude that menopause may worsen RA.

In fact, Young did just that. "Menopausal symptoms may compound the existing symptom burden of RA," she said, adding, "Women with RA will benefit" if their rheumatologists take account of menopause.

In discussing the background to the study, Young referenced a British survey of RA patients that included 612 women who were going through menopause, or had done so. Some 80% said their RA symptoms had worsened during menopause. Moreover, Young said, most (93%, according to the original paper) said their rheumatologic care teams never asked at routine visits about how menopause was affecting them.

For the current study, Young and colleagues drew on two datasets compiled at Mayo: the Data Registry on Experiences of Aging, Menopause, and Sexuality, which consisted of women seeking specialized menopause care; and a group of older women receiving broader care called the Hormones and Experiences of Aging cohort. In total, 9,356 women were included in these registries, of whom 215 had RA.

The patient-reported MRS instrument covers three domains: psychological, somatic, and urogenital. The first comprises mood and fatigue; somatic symptoms include hot flashes, sleep, and musculoskeletal complaints; and sexual, bladder, and vaginal symptoms make up the urogenital domain. Eleven questions are posed, with 0-4 points awarded on each for increasing severity. The maximum is therefore 44, but scores that high are vanishingly rare. Total scores of 17 or more are considered severe, and 9-16 is considered moderate. Young and colleagues set 12 as the threshold for a clinically significant burden.

Mean age in the two cohorts was about 54, both for the RA and non-RA participants. More than 90% were white and about 35% had obesity. Roughly 60% were in menopause when completing the MRS, about 10% were perimenopausal, and the rest were postmenopausal. Relatively few were taking hormone therapy. Also, about 500 participants had non-RA autoimmune diseases including lupus, multiple sclerosis, psoriasis, and inflammatory bowel disease.

For the main MRS-based outcomes, the RA group was compared with the entire registry sample that (for reasons Young didn't discuss) included the RA patients as well as those with other autoimmune conditions. Had the RA patients been separated, however, it probably wouldn't have changed the statistics very much, since they accounted for only 2% of the total. And some analyses did compare RA with non-RA participants.

Psychological and urogenital symptom burdens with menopause did not appear worsened at all with RA -- only somatic symptoms seemed to be exacerbated. Total somatic scores averaged 6 in the RA group versus 5 in the total sample. A greater difference was seen when looking at clinically significant burdens in the somatic domain, defined as an MRS score of at least 8. In this comparison, 20% of the total sample had a significant burden, compared with 31% of RA patients.

And joint pain was not solely responsible for this latter difference. Compared with non-RA participants, more of those with RA reported moderate, severe, and very severe hot flashes (49% vs 41%, P=0.024).

Another analysis compared the RA group with participants having other autoimmune conditions on total MRS scores, proportions with clinically significant menopause burdens, and severe hot flashes. Only with RA were these worse than in the total sample, although the smaller numbers of patients with non-RA autoimmune diseases render these differences less reliable. (Interestingly, prevalence of severe hot flashes appeared lower in lupus patients.)

Young noted that the databases didn't include information on RA severity, an important limitation insofar as RA symptoms overlap so much with those of menopause. As well, the study was restricted to women seen at the Mayo Clinic, who may not be representative of either the general population or those with RA.

来源:MedPage Today · medpagetoday.com